Published Online
on July 14, 2008

A more recent version of this article appeared on July 29, 2008

This Article Full Text (PDF) Data Supplement All Versions of this Article: 118/5/507    most recent CIRCULATIONAHA.108.778795v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mauritz, C. Articles by Martin, U. Search for Related Content PubMed PubMed Citation Articles by Mauritz, C. Articles by Martin, U. Related Collections Myogenesis Cardiac development Related Article

Submitted on March 10, 2008
Accepted on May 12, 2008

Generation of Functional Murine Cardiac Myocytes From Induced Pluripotent Stem Cells

Christina Mauritz DVM, Kristin Schwanke PhD, Michael Reppel MD, Stefan Neef MD, Katherina Katsirntaki , Lars S. Maier MD, Filomain Nguemo PhD, Sandra Menke , Moritz Haustein , Juergen Hescheler MD, Gerd Hasenfuss MD, and Ulrich Martin PhD^*

From the Leibniz Research Laboratories for Biotechnology and Artificial Organs, Department of Cardiac, Thoracic, Transplantation, and Vascular Surgery, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany (C.M., K.S., K.K., S.M., U.M.); Institute of Neurophysiology, University of Cologne, Cologne, Germany (M.R., F.N., M.H., J.H.); Department of Cardiology, University of Luebeck, Luebeck, Germany (M.R.); and Department of Cardiology and Pneumology, University Medical Center Goettingen, Goettingen, Germany (S.N., L.S.M., G.H.).

^* To whom correspondence should be addressed. E-mail: martin.ulrich{at}mh-hannover.de.

Background—The recent breakthrough in the generation of induced pluripotent stem (iPS) cells, which are almost indistinguishable from embryonic stem (ES) cells, facilitates the generation of murine disease– and human patient–specific stem cell lines. The aim of this study was to characterize the cardiac differentiation potential of a murine iPS cell clone in comparison to a well-established murine ES cell line.

Methods and Results—With the use of a standard embryoid body–based differentiation protocol for ES cells, iPS cells as well as ES cells were differentiated for 24 days. Although the analyzed iPS cell clone showed a delayed and less efficient formation of beating embryoid bodies compared with the ES cell line, the differentiation resulted in an average of 55% of spontaneously contracting iPS cell embryoid bodies. Analyses on molecular, structural, and functional levels demonstrated that iPS cell–derived cardiomyocytes show typical features of ES cell–derived cardiomyocytes. Reverse transcription polymerase chain reaction analyses demonstrated expression of marker genes typical for mesoderm, cardiac mesoderm, and cardiomyocytes including Brachyury, mesoderm posterior factor 1 (Mesp1), friend of GATA2 (FOG-2), GATA-binding protein 4 (GATA4), NK2 transcription factor related, locus 5 (Nkx2.5), T-box 5 (Tbx5), T-box 20 (Tbx20), atrial natriuretic factor (ANF), myosin light chain 2 atrial transcripts (MLC2a), myosin light chain 2 ventricular transcripts (MLC2v), -myosin heavy chain (-MHC), and cardiac troponin T in differentiation cultures of iPS cells. Immunocytology confirmed expression of cardiomyocyte-typical proteins including sarcomeric -actinin, titin, cardiac troponin T, MLC2v, and connexin 43. iPS cell cardiomyocytes displayed spontaneous rhythmic intracellular Ca²⁺ fluctuations with amplitudes of Ca²⁺ transients comparable to ES cell cardiomyocytes. Simultaneous Ca²⁺ release within clusters of iPS cell–derived cardiomyocytes indicated functional coupling of the cells. Electrophysiological studies with multielectrode arrays demonstrated functionality and presence of the -adrenergic and muscarinic signaling cascade in these cells.

Conclusions—iPS cells differentiate into functional cardiomyocytes. In contrast to ES cells, iPS cells allow derivation of autologous functional cardiomyocytes for cellular cardiomyoplasty and myocardial tissue engineering.

Key words: myocytes • stem cells • differentiation

Related Article:

Clinical Summaries
Circulation 2008 118: 465-466. [Extract] [Full Text]

This article has been cited by other articles:

				R. David, J. Stieber, E. Fischer, S. Brunner, C. Brenner, S. Pfeiler, F. Schwarz, and W.-M. Franz Forward programming of pluripotent stem cells towards distinct cardiovascular cell types Cardiovasc Res, November 1, 2009; 84(2): 263 - 272. [Abstract] [Full Text] [PDF]

				L. Zwi, O. Caspi, G. Arbel, I. Huber, A. Gepstein, I.-H. Park, and L. Gepstein Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells Circulation, October 13, 2009; 120(15): 1513 - 1523. [Abstract] [Full Text] [PDF]

				K. Schenke-Layland and W. R. MacLellan Induced Pluripotent Stem Cells: It's Like Deja Vu All Over Again Circulation, October 13, 2009; 120(15): 1462 - 1464. [Full Text] [PDF]

				T. J. Kamp and G. E. Lyons On the Road to iPS Cell Cardiovascular Applications Circ. Res., September 25, 2009; 105(7): 617 - 619. [Full Text] [PDF]

				A. Martinez-Fernandez, T. J. Nelson, S. Yamada, S. Reyes, A. E. Alekseev, C. Perez-Terzic, Y. Ikeda, and A. Terzic iPS Programmed Without c-MYC Yield Proficient Cardiogenesis for Functional Heart Chimerism Circ. Res., September 25, 2009; 105(7): 648 - 656. [Abstract] [Full Text] [PDF]

				T. J. Nelson, A. Martinez-Fernandez, S. Yamada, C. Perez-Terzic, Y. Ikeda, and A. Terzic Repair of Acute Myocardial Infarction by Human Stemness Factors Induced Pluripotent Stem Cells Circulation, August 4, 2009; 120(5): 408 - 416. [Abstract] [Full Text] [PDF]

				D. M. Dalgetty, C. N. Medine, J. P. Iredale, and D. C. Hay Progress and future challenges in stem cell-derived liver technologies Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G241 - G248. [Abstract] [Full Text] [PDF]

				K. D. Boudoulas and A. K. Hatzopoulos Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease Dis. Model. Mech., July 1, 2009; 2(7-8): 344 - 358. [Abstract] [Full Text] [PDF]

				U. Landmesser Bone marrow cell therapy after myocardial infarction. What should we select? Eur. Heart J., June 1, 2009; 30(11): 1310 - 1312. [Full Text] [PDF]

				H. Q. Ly and S. Nattel Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle Circulation, April 7, 2009; 119(13): 1824 - 1831. [Full Text] [PDF]

				J. Zhang, G. F. Wilson, A. G. Soerens, C. H. Koonce, J. Yu, S. P. Palecek, J. A. Thomson, and T. J. Kamp Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells Circ. Res., February 27, 2009; 104(4): e30 - e41. [Abstract] [Full Text] [PDF]

				A. J. Engler, C. Carag-Krieger, C. P. Johnson, M. Raab, H.-Y. Tang, D. W. Speicher, J. W. Sanger, J. M. Sanger, and D. E. Discher Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating J. Cell Sci., November 15, 2008; 121(22): 3794 - 3802. [Abstract] [Full Text] [PDF]

				N. L. Tulloch, L. Pabon, and C. E. Murry Get With the (Re)Program: Cardiovascular Potential of Skin-Derived Induced Pluripotent Stem Cells Circulation, July 29, 2008; 118(5): 472 - 475. [Full Text] [PDF]